In vitro evaluation of enteral tube administration of lansoprazole orally disintegrating tablets
Lansoprazole orally disintegrating tablets (ODTs) can be administered orally or through a nasogastric (NG) tube for patients who are unable to swallow. In addition, off-label administration through gastrostomy (G) or jejunal (J) tubes has been reported. The purpose of this study was to develop in vitro methods to assess the risk of clogging during administration of two lansoprazole ODTs through enteral feeding tubes. Feeding tubes of various compositions and geometries were selected for testing. Disintegration, sedimentation, percent recovery, acid phase dissolution testing, and particle size distribution measurements were performed. The results indicated that G tubes had the greatest risk of clogging compared to NG and J tubes. In addition, larger particles and an increased amount of insoluble excipients observed in Product B resulted in more irreversible enteral tube clogging than compared to Product A. The geometry and design of the tube also had an impact on the amount of lansoprazole recovered after enteral tube administration. Lansoprazole ODTs demonstrated acid resistance stability regardless of the water used for suspension. The in vitro methods discussed in this work could be used to evaluate in vitro equivalence and to assess the risk of delivering a drug product through an enteral feeding tube.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Pharmaceutical development and technology - 26(2021), 8 vom: 29. Okt., Seite 846-851 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hoover, Alicia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0K5C5T2QPG |
|---|
| Anmerkungen: |
Date Completed 07.01.2022 Date Revised 07.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10837450.2021.1948567 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327298685 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327298685 | ||
| 003 | DE-627 | ||
| 005 | 20231225200453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10837450.2021.1948567 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327298685 | ||
| 035 | |a (NLM)34182865 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hoover, Alicia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vitro evaluation of enteral tube administration of lansoprazole orally disintegrating tablets |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.01.2022 | ||
| 500 | |a Date Revised 07.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Lansoprazole orally disintegrating tablets (ODTs) can be administered orally or through a nasogastric (NG) tube for patients who are unable to swallow. In addition, off-label administration through gastrostomy (G) or jejunal (J) tubes has been reported. The purpose of this study was to develop in vitro methods to assess the risk of clogging during administration of two lansoprazole ODTs through enteral feeding tubes. Feeding tubes of various compositions and geometries were selected for testing. Disintegration, sedimentation, percent recovery, acid phase dissolution testing, and particle size distribution measurements were performed. The results indicated that G tubes had the greatest risk of clogging compared to NG and J tubes. In addition, larger particles and an increased amount of insoluble excipients observed in Product B resulted in more irreversible enteral tube clogging than compared to Product A. The geometry and design of the tube also had an impact on the amount of lansoprazole recovered after enteral tube administration. Lansoprazole ODTs demonstrated acid resistance stability regardless of the water used for suspension. The in vitro methods discussed in this work could be used to evaluate in vitro equivalence and to assess the risk of delivering a drug product through an enteral feeding tube | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Drug administration | |
| 650 | 4 | |a analytical methods | |
| 650 | 4 | |a enteral tube | |
| 650 | 4 | |a lansoprazole | |
| 650 | 7 | |a Lansoprazole |2 NLM | |
| 650 | 7 | |a 0K5C5T2QPG |2 NLM | |
| 700 | 1 | |a Chitranshi, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Momot, Magdalene |e verfasserin |4 aut | |
| 700 | 1 | |a Tyner, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Wokovich, Anna |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical development and technology |d 1998 |g 26(2021), 8 vom: 29. Okt., Seite 846-851 |w (DE-627)NLM094740194 |x 1097-9867 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2021 |g number:8 |g day:29 |g month:10 |g pages:846-851 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10837450.2021.1948567 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2021 |e 8 |b 29 |c 10 |h 846-851 | ||